Myox Use In Pregnancy & Lactation

Pregnancy: There are no clinical data on exposed pregnancy for etoricoxib. Animal studies have shown reproductive toxicity. The potential for human risk is unknown.
Etoricoxib is a prostaglandin synthesis inhibitor, and may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester. Data from epidemiological studies demonstrate an increased risk of miscarriage after using a prostaglandin synthesis inhibitor during early pregnancy. Etoricoxib is contraindicated in pregnant women and should be discontinued if the patient becomes pregnant.
Lactation: It is not known if etoricoxib is excreted in human milk. Because of the potential risk to breastfed infants, a decision should be made whether to discontinue breastfeeding or to discontinue etoricoxib, taking into consideration the importance of the drug to the mother. Etoricoxib is contraindicated in breastfeeding women.
Effects on Sexual Function and Fertility: As with any medicinal product that inhibits COX/prostaglandin synthesis, the use of etoricoxib is not recommended in women attempting to conceive.